SeaStar Medical Holding Corporation reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated $183,000 in revenue for the third quarter, a substantial increase from $68,000 in the same period last year. For the nine months ended September 30, 2025, total revenue reached $814,000, compared to just $68,000 for the same period in 2024. The increase in revenue is attributed to the commercial launch of its pediatric Selective Cytopheretic Device (SCD), QUELIMMUNE, which received FDA approval in February 2024 and began shipping in July 2024.
Despite the revenue growth, SeaStar reported a net loss of $3.5 million for the third quarter, an improvement from a loss of $4.5 million in the prior year. For the nine-month period, the net loss was $9.2 million, significantly reduced from $20.4 million in 2024. The company’s operating expenses also decreased, with total operating expenses for the third quarter at $3.7 million, down from $4.5 million a year earlier. This reduction was primarily due to lower research and development costs, which fell to $1.9 million from $2.3 million, and general and administrative expenses, which decreased to $1.9 million from $2.2 million.
Operationally, SeaStar has made strides in expanding its customer base, with nine customer sites for QUELIMMUNE as of September 30, 2025. The company has also been actively involved in clinical trials for its adult SCD, which is currently in a pivotal study to assess its safety and efficacy in critically ill patients. The company’s total assets increased to $15.5 million as of September 30, 2025, up from $4.7 million at the end of 2024, largely due to successful capital raises through various equity offerings.
Looking ahead, SeaStar faces challenges regarding its liquidity and ability to continue as a going concern. The company reported cash reserves of $13.8 million as of September 30, 2025, which it believes may not be sufficient to fund operations for the next 12 months without additional capital. The company plans to finance its operations through equity or debt financing, collaborations, or grants, but acknowledges that adequate capital may not be available when needed. The ongoing need for funding raises substantial doubt about the company's ability to sustain its operations and continue its development programs.
About SeaStar Medical Holding Corp
SeaStar Medical Holding Corporation develops extracorporeal medical devices targeting hyperinflammation and organ failure. Its flagship product, the Selective Cytopheretic Device (SCD), modulates immune cells to treat acute and chronic inflammatory conditions, including acute kidney injury, cardiorenal syndrome, and liver failure. The company focuses on regulatory approval, clinical trials, and strategic partnerships to commercialize its innovative, organ-agnostic therapy for critically ill patients worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.